Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy

• Autor(a) principal: Geraix, Juliana [UNESP]
• Data de Publicação: 2006
• Outros Autores: de Souza, Micheli Evangelista [UNESP], Delatim, Francieli Cristina [UNESP], Pereira, Paulo Câmara Marques [UNESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• DOI: 10.1590/S1413-86702006000300001
• Texto Completo: http://dx.doi.org/10.1590/S1413-86702006000300001; http://hdl.handle.net/11449/68900
• topic: Bezafibrate; HAART; HIV; Hypertriglyceridemia; antiretrovirus agent; bezafibrate; CD4 antigen; CD8 antigen; cedura retard; creatine kinase; liver enzyme; proteinase inhibitor; RNA directed DNA polymerase inhibitor; triacylglycerol; adult; alcohol consumption; cardiovascular disease; clinical article; controlled study; creatine kinase blood level; diabetes mellitus; drug dose regimen; drug efficacy; drug safety; dyslipidemia; family history; female; follow up; highly active antiretroviral therapy; human; Human immunodeficiency virus 1; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; hypertension; hypertriglyceridemia; male; nonhuman; obesity; sitting; smoking; triacylglycerol blood level; virus load; Adult; Antilipemic Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; Female; HIV Infections; Humans; Male; Treatment Outcome; Viral Load

The use of highly active antiretroviral therapy (HAART) in HIV-infected patients has been associated with the development of risk factors for cardiovascular diseases (CD) including dyslipidemia and insulin resistance, hypertriglyceridemia being the most frequent metabolic disturbance in these patients. Fibrates are indicated when hypertriglyceridemia is accentuated and persists for over six months. We evaluated the efficacy and safety of bezafibrate for the treatment of hypertriglyceridemia in HIV-infected individuals on HAART. All patients received 400mg/day of bezafibrate and were evaluated three times: Mo (pre-treatment), M1 (one month after treatment), and M2 (six months after treatment). Fifteen adult individuals, eight males and seven females with mean age = 41.2 ± 7.97 years and triglyceride serum levels ≥400mg/dL were included in the study. Smoking, alcohol ingestion and sedentarism rates were 50%, 6.66% and 60%, respectively. Family history of CD, hypertension and diabetes mellitus was reported in 33.3%, 40% and 46.7% of the cases, respectively, while dyslipidemia was reported by only 13.3%. More than half of the patients were using a protease inhibitor plus a nucleotide analog transcriptase inhibitor. Eutrophy and tendency toward overweight were observed at all three study time points. There were significant reductions in triglyceride serum levels from Mo to M1 and from Mo to M2. No significant changes were observed in the serum levels of creatine phosphokinase, hepatic enzymes, CD4 +, CD8 + and viral load. Therefore, bezafibrate seems to be safe and effective for the reduction of hypertriglyceridemia in HIV-infected patients on HAART. © 2006 by The Brazilian Journal of Infectious Diseases and Contexto Publishing. All rights reserved.